sofosbuvir + daclatasvir + CDI-31244

This is an investigational oral antiviral combination therapy consisting of three direct-acting antivirals targeting hepatitis C virus (HCV): sofosbuvir, daclatasvir, and CDI-31244. Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase. Daclatasvir is an inhibitor of the HCV NS5A protein. CDI-31244 (also called CC-31244) is a non-nucleoside inhibitor (NNI) that targets the HCV NS5B polymerase at a different site from sofosbuvir and has broad-spectrum activity against all major HCV genotypes with a high barrier to resistance[8][10]. The rationale behind this triple regimen is to achieve ultrashort duration therapy while maintaining high cure rates by combining agents with complementary mechanisms and resistance profiles.

Brand names

none known for the triple combination; individual components have brand names (Sovaldi for sofosbuvir, Daklinza for daclatasvir)

Other names

none known for the triple combination